JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Happe, H. K.
Right arrow Articles by Murrin, L. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Happe, H. K.
Right arrow Articles by Murrin, L. C.

Vol. 288, Issue 3, 1134-1142, March 1999

Alpha-2 Adrenergic Receptor Functional Coupling to G Proteins in Rat Brain During Postnatal Development1

H. Kevin Happe, David B. Bylund and L. Charles Murrin

Departments of Pharmacology (H.K.H., D.B.B., L.C.M.) and Internal Medicine Neurology Section (L.C.M.), University of Nebraska Medical Center, Omaha, Nebraska

During postnatal development, alpha-2 adrenergic receptors (A2AR) change in both density and distribution. In forebrain, receptor density increases about 4-fold over neonatal levels, reaching adult levels before postnatal day (P) 28, whereas in hindbrain, including cerebellum, there is a decrease in overall receptor density. We examined the coupling of A2AR to G proteins using agonist-stimulated [35S]GTPgamma S binding as a functional assay. In forebrain the A2AR agonist-stimulated [35S]GTPgamma S binding increases rapidly after P7, reaching its highest levels at P21 and then declining slightly to adult levels. This binding increases more slowly than receptor number, suggesting that the appearance of G proteins, rather than the A2AR, determines the developmental appearance of functional A2AR-G protein interactions in forebrain. Basal [35S]GTPgamma S binding and [35S]GTPgamma S binding stimulated by other neurotransmitter receptor systems (GABA-B, mu opiate, and muscarinic) increase with a time course similar to A2AR-stimulated [35S]GTPgamma S binding. In contrast, in hindbrain, A2AR-stimulated [35S]GTPgamma S binding decreases during postnatal development in parallel with the decrease in A2AR levels, whereas [35S]GTPgamma S binding stimulated by other neurotransmitter receptor systems increases in parallel with basal [35S]GTPgamma S binding. Functional receptor-G protein coupling in hindbrain appears to be dependent on the developmental appearance of G proteins for most neurotransmitter systems. However, for A2AR the decrease in receptor density is the overriding factor. These studies 1) demonstrate the functional measurement of A2AR-G protein coupling in native tissue for the first time, 2) demonstrate that A2AR are coupled to G proteins throughout postnatal development, and 3) describe developmental increases and decreases in functional A2AR in brain.


0022-3565/99/2883-1134$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 1999 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
J. N. Talbot, H. K. Happe, and L. C. Murrin
{micro} Opioid Receptor Coupling to Gi/o Proteins Increases during Postnatal Development in Rat Brain
J. Pharmacol. Exp. Ther., August 1, 2005; 314(2): 596 - 602.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
S. Guimaraes and D. Moura
Vascular Adrenoceptors: An Update
Pharmacol. Rev., June 1, 2001; 53(2): 319 - 356.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1999 by the American Society for Pharmacology and Experimental Therapeutics.